DELEX Pharma’s legacy is built on 15 years of sustained growth. The company’s leadership team, with over three decades of experience in the healthcare sector, its in-demand products, strong marketing teams, networks and partnerships across the region, has played an integral role in driving this growth and positioning DELEX as a powerhouse within the industry.
At the helm of DELEX is a group of seasoned leaders with extensive experience in both the pharmaceutical and medical industries. With a highly experienced management team at the helm, this leadership ensures the company’s future success as they continue to execute on their ambitious vision for the future. Investors can look to DELEX as a company poised for long-term success and well positioned for continued market leadership and increased shareholder value.
DELEX Pharma is ranked as the third-largest national player in the hospital channel market according to IQVIA. Their entrepreneurial acumen and expertise, honed through years of working with multinational healthcare giants, empower DELEX to continually adapt and thrive in a competitive market and be a dominant player in the healthcare market.
From importing and distributing pharmaceutical products to running drugstores and medical devices, DELEX is fully equipped to meet the regulatory standards that govern the diverse landscape of the Philippine healthcare industry. DELEX Pharma currently holds various licenses and permits issued by the Philippines Food and Drug administration for (i) Importer/ Wholesaler/Distributor of Drugs (ii) Importer of Medical Devices (iii) Food Wholesaler, (iv) Cosmetic Importer and Wholesaler and (v) Drugstore Operator, including Online Order and Delivery.
DELEX Pharma is committed to continuously expanding its product portfolio to meet the needs of both healthcare professionals and patients. With over 30 FDA-approved hospital products and numerous medical device products, DELEX is pushing the boundaries of innovation. The company’s recent launch of 11 new pharmaceutical products and strategic partnerships with multinational medical device firms demonstrates its aggressive expansion strategy across multiple therapeutic and diagnostic areas.
With a network that already supplies to over 900 pharmacies and hospitals nationwide, DELEX is positioned for even greater reach. By building on its strong distribution network and forming strategic partnerships with healthcare providers, DELEX aims to expand its footprint, enhancing its market development and creating integrated healthcare solutions to improve patient outcomes.
The medical device market in the Philippines is experiencing rapid growth, and DELEX is well-positioned to capitalize on this opportunity. With a strategic alliance with leading international companies such as Amsino, Masimo, and Verathon, DELEX aims to be a key player in the medical device sector. These collaborations will not only enhance DELEX’s offerings but also solidify its position as a leading distributor of high-quality healthcare solutions.
Building on the success of its first pharmacy branch opened in 2021, DELEX plans to expand its retail pharmacy business to 60 locations in the coming years. This expansion comes at a time when the pharmacy market is poised for significant growth, driven by increased demand for pharmaceutical services and products. DELEX’s strategy of situating drugstores near hospitals and high-traffic areas is a smart move to generate strong sales and meet the needs of the community.
As the healthcare landscape becomes increasingly digital, DELEX is tapping into the rapidly growing ePharmacy market. Through its online platform, DELEX offers a seamless 24/7 ordering and delivery service for a wide range of over-the-counter medicines, prescription drugs, and health products. As the Philippines’ ePharmacy market continues to expand, DELEX is set to capture a broad customer base and meet the demand for convenient, cost-effective healthcare solutions.
DELEX has proven its commitment to improving healthcare outcomes through educational initiatives such as the DELEX ICU Forum. What began as an in-person event has grown into a powerful online platform that has attracted nearly 200,000 healthcare professionals worldwide. The forum facilitates important conversations on critical care advancements, treatment protocols, and best practices, further solidifying DELEX’s role as a thought leader in the healthcare space.
With a robust infrastructure that includes a dedicated trade sales team and state-of-the-art SAP ERP systems, DELEX Pharma ensures efficient distribution and inventory management. This operational efficiency allows DELEX to respond promptly to customer demands and maintain high levels of service across its entire distribution network.
In 2022, DELEX Pharma made a significant move to acquire JMN Brothers Pharma Limited, a company known for its expertise in women’s health and beauty. This acquisition enables DELEX to expand its hospital product portfolio and tap into new market segments, further diversifying its offerings and increasing its market share in the healthcare sector.
DELEX Pharma’s commitment to quality and operational excellence has been recognized globally. The company recently underwent and passed the ISO 9001:2015 re-certification, underscoring its dedication to meeting international quality standards and providing superior products and services to its customers.
DELEX’s track record of success is reflected in the numerous accolades and awards the company has received. These include recognition as the “Diversity Company of the Year” and “SME Company of the Year” by the Asia CEO Awards, as well as individual honors for its leadership team. These awards affirm DELEX’s position as a top-tier healthcare company in the Philippines.
